抗乙型肝炎免疫核糖核酸联合口服阿昔洛韦治疗慢性乙型肝炎对血清HBV标志的影响  

Effects of Anti-Hepatitis B iRNA and Acyclovir on HBV Seroigical Markers in Chronic Hepatitis B Patients

作　　者：许西平[1] 

机构地区：[1]湖北医科大学附二医院传染科,武汉430071

出　　处：《湖北医科大学学报》1996年第1期78-80,共3页

摘　　要：将 HBV 复制指标阳性的慢性乙型肝炎(慢乙肝)不同治疗的82侧随机分3组:单一药物组:应用抗乙型肝炎免疫核糖核酸;联合药物组:抗乙型肝炎免痰核糖核酸联合口服阿昔洛韦;对照组:肝泰乐。分别治疗慢乙肝井对血清 HBV 进行了对比观察。治疗结束后半年,联合药物组 HBsAg、HBeAg、抗HBc-IgM、HBV-DNA 阴转事分别为26.3%、52.6%、63.6%、64.4%及抗-HBs、抗-HBe 阳转率分别为10.5%、42.1%;单一药物组分别为16.7%、40.5%、48.1%、30.4%及4.8%、33.3%;对照组分别为4.8%、19.0%、0%、0%及0%、14.3%。结果表明:抗乙型肝炎免疫核糖核酸联合阿昔洛韦对清除和抑制HBV 有较明显的效果。82 chronic hepatitis B patients with HBV replicative marker positive are randomly divided in- to 3 groups,for which the simple drug is administered with anti-hepatitis B iRNA.The allied drug administered is both anti-hepatitis B iRNA and acyclovir and the control is administered with glucuronolactoni.In half year after the treatment,the experimental rasult shows that the negative alternative rates of HBsAg,HBeAg,anti-HBcIand HBV-DNA are 26.3%,52.6%, 63.6% and 64.4% respectively and the positive alternative rates of anti-HBs and anti-HBe are 10.5% and 42.1% respectively in the allied drug.While 16.7%,40.5%,48.1%,30.4%,4.8% and 33.3 %,respectively in the simple drug ;and 4.8 %,19.0 %,0,0 and 0,14.3 % respectively in the control.It is suggested that anti-hepatitis B iRNA combined with acyclovir has good effects on clearance and inhibition of HBV.

关 键 词：乙型肝炎 嘌呤核苷酸 药物疗法 阿昔洛韦 

分 类 号：R512.620.5[医药卫生—内科学]